#1 Clinical Trials Search in Europe

Ixazomib Citrate

This article explores the use of Ixazomib Citrate, a novel oral proteasome inhibitor, in clinical trials for treating multiple myeloma. Multiple myeloma is a type of blood cancer that affects plasma cells. Researchers are investigating Ixazomib Citrate alone and in combination with other drugs to improve outcomes for patients with newly diagnosed, relapsed, or refractory multiple myeloma. The trials aim to evaluate the drug’s safety, efficacy, and potential to enhance or restore sensitivity to other treatments.

Table of Contents

What is IXAZOMIB?

IXAZOMIB, also known by its research name MLN9708, is a medication used in the treatment of certain blood cancers[1]. It belongs to a class of drugs called proteasome inhibitors, which work by interfering with the way cancer cells process proteins[2]. IXAZOMIB is available in capsule form for oral administration, making it more convenient for patients compared to some other cancer treatments that require injections or infusions[3].

How Does IXAZOMIB Work?

IXAZOMIB works by inhibiting the 20S proteasome, which is a complex within cells responsible for breaking down proteins[2]. By blocking this process, IXAZOMIB causes an accumulation of proteins within cancer cells, leading to cell death. This mechanism is particularly effective against certain types of cancer cells that rely heavily on protein processing for their survival and growth[1].

What Conditions Does IXAZOMIB Treat?

IXAZOMIB is primarily used in the treatment of the following conditions:

  • Multiple Myeloma: This is a type of blood cancer that affects plasma cells, a type of white blood cell[4]. IXAZOMIB is often used in combination with other drugs like lenalidomide and dexamethasone for newly diagnosed multiple myeloma or in patients who have relapsed after previous treatments[5].
  • Systemic Light Chain (AL) Amyloidosis: This is a rare disease where abnormal proteins build up in organs, causing them to malfunction. IXAZOMIB has shown promise in treating relapsed or refractory (difficult to treat) cases of this condition[3].
  • Lymphoma: Some clinical trials have explored the use of IXAZOMIB in certain types of lymphoma, which are cancers that begin in cells of the lymph system[2].

How is IXAZOMIB Administered?

IXAZOMIB is typically taken orally in capsule form. The dosing schedule can vary depending on the specific condition being treated and whether it’s being used alone or in combination with other medications. Some common dosing regimens include:

  • Once weekly on days 1, 8, and 15 of a 28-day cycle[4]
  • Twice weekly on days 1, 4, 8, and 11 of a 21-day cycle[5]

The dose may be adjusted based on how well a patient tolerates the medication and their response to treatment. It’s important for patients to take IXAZOMIB exactly as prescribed by their healthcare provider[6].

IXAZOMIB in Clinical Trials

IXAZOMIB has been the subject of numerous clinical trials to evaluate its safety and effectiveness. These trials have explored its use in various scenarios, including:

  • As a maintenance therapy after stem cell transplantation in multiple myeloma patients[6]
  • In combination with other drugs for newly diagnosed multiple myeloma[5]
  • For relapsed or refractory multiple myeloma[1]
  • In patients with systemic light chain amyloidosis[3]
  • For various types of lymphoma[2]

These trials have helped establish the appropriate dosing, efficacy, and safety profile of IXAZOMIB in different patient populations.

Potential Side Effects

Like all medications, IXAZOMIB can cause side effects. Some of the most commonly reported side effects include:

  • Gastrointestinal issues: Such as nausea, vomiting, diarrhea, and constipation[3]
  • Fatigue: Feeling tired or weak is a common side effect[4]
  • Peripheral neuropathy: This can cause numbness, tingling, or pain in the hands and feet[1]
  • Low blood cell counts: Including low platelet counts (thrombocytopenia) and low white blood cell counts (neutropenia), which can increase the risk of bleeding and infections[5]
  • Skin rash: Some patients may experience skin reactions[6]

It’s important for patients to report any side effects to their healthcare provider, as some may require dose adjustments or additional management strategies.

Effectiveness of IXAZOMIB

Clinical trials have shown that IXAZOMIB can be effective in improving outcomes for patients with multiple myeloma and other conditions. Some key findings include:

  • Improved progression-free survival when used as maintenance therapy after stem cell transplantation in multiple myeloma patients[6]
  • High response rates when used in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma[5]
  • Promising results in patients with relapsed or refractory systemic light chain amyloidosis[3]

The effectiveness of IXAZOMIB can vary depending on the individual patient, the specific condition being treated, and whether it’s being used alone or in combination with other medications. Patients should discuss their treatment options and expected outcomes with their healthcare provider.

Aspect Details
Drug Name Ixazomib Citrate (also known as MLN9708)
Drug Class Oral proteasome inhibitor
Primary Conditions Studied Multiple Myeloma (newly diagnosed, relapsed, and refractory)
Common Combination Therapies Lenalidomide, Dexamethasone, Rituximab, Thalidomide, Venetoclax
Administration Oral capsules, typically given on days 1, 8, and 15 of a 28-day cycle
Key Outcome Measures Overall Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), Minimal Residual Disease (MRD) negativity
Patient Populations Newly diagnosed, transplant-ineligible, relapsed/refractory, post-transplant maintenance
Safety Assessments Adverse events, tolerability, dose-limiting toxicities
Biomarker Studies BCL2, NOXA, MCL1 expression, pharmacokinetic analysis
Trial Phases Phase 1, Phase 2, and Phase 3 studies

FAQ

  • What is Ixazomib Citrate? Ixazomib Citrate is an oral proteasome inhibitor being studied for the treatment of multiple myeloma. It works by blocking enzymes that cancer cells need to grow, potentially stopping or slowing the growth of cancer cells.
  • How is Ixazomib Citrate administered in clinical trials? In most trials, Ixazomib Citrate is given orally as a capsule, typically on days 1, 8, and 15 of a 28-day treatment cycle. The dosage may vary depending on the specific trial and combination therapy used.
  • What are some common drug combinations being tested with Ixazomib Citrate? Ixazomib Citrate is being tested in various combinations, including with lenalidomide and dexamethasone, rituximab, thalidomide, and venetoclax. These combinations aim to enhance the effectiveness of treatment for multiple myeloma.
  • What types of multiple myeloma patients are being included in these trials? The trials include patients with newly diagnosed multiple myeloma, as well as those with relapsed or refractory disease. Some studies focus on specific patient groups, such as those who are not eligible for stem cell transplantation or those who have become resistant to certain treatments.
  • What are the main goals of these clinical trials? The main goals of these trials include determining the safety and efficacy of Ixazomib Citrate, finding the optimal dosage, evaluating its effectiveness in combination with other drugs, and assessing outcomes such as overall response rate, progression-free survival, and overall survival in multiple myeloma patients.

Ongoing Clinical Trials on Ixazomib Citrate

  • Study of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

  • Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany

  • Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Norway +1

  • Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia Greece Italy

  • Study on the Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone in Treating Newly Diagnosed Multiple Myeloma in Patients Eligible for Transplant

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Lithuania Norway Sweden

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections.
  • Proteasome Inhibitor: A type of drug that blocks the action of proteasomes, which are cellular complexes that break down proteins. By inhibiting proteasomes, these drugs can cause cancer cells to die.
  • Relapsed Multiple Myeloma: Multiple myeloma that has returned after a period of remission or response to treatment.
  • Refractory Multiple Myeloma: Multiple myeloma that does not respond to treatment or stops responding to treatment.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment, often undetectable by standard tests.
  • Autologous Stem Cell Transplant (ASCT): A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to restore blood cell production.
  • International Myeloma Working Group (IMWG) Criteria: Standardized guidelines used to assess response to treatment and disease progression in multiple myeloma.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug recommended for further testing in phase 2 clinical trials, based on results from phase 1 studies.
  • Bruton's Tyrosine Kinase (BTK) Inhibitor: A type of drug that blocks the action of BTK, an enzyme important for B-cell and cancer cell survival and proliferation.

References

  1. https://clinicaltrials.gov/study/NCT00963820
  2. https://clinicaltrials.gov/study/NCT00893464
  3. https://clinicaltrials.gov/study/NCT01659658
  4. https://clinicaltrials.gov/study/NCT01850524
  5. https://clinicaltrials.gov/study/NCT01383928
  6. https://clinicaltrials.gov/study/NCT02181413